DUBLIN, March 14, 2017 /PRNewswire/ — Results of a recent survey commissioned by Allergan plc to better understand the personal impact of submental fullness as well as how others perceive individuals with submental fullness were revealed at the American Academy of Dermatology (AAD) Meeting in Orlando, FL. 1,996 men and women in the U.S. between the ages of 18 and 65 were surveyed to better understand how having a double chin plays a role in self-perception and alternatively, how those with submental fullness are viewed by others.1
Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8061651-allergan-kybella-double-chin-survey/
Results of the survey revealed:
Impact of Submental Fullness on Self-Perception, Behavior and Social Perceptions
„We understand that submental fullness is a common concern,4” says David Moatazedi, Senior Vice-President of Facial Aesthetics at Allergan. „It was important for us to dig deeper to better understand the substantial impact that submental fullness may have on patients’ self-perception and behavior, as well as the perception others may have of individuals with submental fullness. Gaining a better understanding of how having a double chin plays a role in self-perception and alternatively, how those with submental fullness are viewed by others will help physicians in their daily interactions with these patients.”
„The results of this survey mimic what I hear from patients on a daily basis – they are bothered by submental fullness and are looking to address the problem. In many cases, the submental fullness is genetic and resistant to diet or exercise,2,3” says Dr. Shannon Humphrey, Board-Certified Dermatologist and Co-Author of this survey. „These findings will help physicians to better understand the impact a double chin has on our patients so we can address this issue and provide them with effective treatment options.”
Allergan is the maker of KYBELLA® (deoxycholic acid) injection 10 mg/mL, the only FDA-approved injectable treatment for adults that destroys fat cells in the treatment area under the chin to improve a patient’s profile – whether they have a moderate amount of chin fullness or a bit more – with no surgery.5 The active ingredient in KYBELLA® is a non-human, non-animal formulation of deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.6 When injected into the fat in the treatment area beneath the chin, KYBELLA® physically destroys fat cells, which makes them unable to accumulate or store fat. 5,6
In clinical studies, 88% of patients received more than one KYBELLA® treatment,7,8 with 59% of patients receiving six KYBELLA® treatments. Everyone has a different level of submental fat and a licensed and trained physician will be able to determine the number of KYBELLA® treatments each patient will need. Multiple injections are given under the chin per treatment and up to 6 treatments can be administered, spaced at least 1 month apart. With KYBELLA®, once the desired result is achieved, retreatment is not expected.5 For more information about KYBELLA® or to find a doctor, please visit www.mykybella.com.
KYBELLA® Indication and Important Safety Information
What is KYBELLA®?
KYBELLA® is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called „double chin.”
It is not known if KYBELLA® is safe and effective for use outside of the submental area or in children under the age of 18.
Who should not receive KYBELLA®?
You should not receive KYBELLA® if you have an infection in the treatment area.
Before receiving KYBELLA®, tell your healthcare provider about all of your medical conditions, including if you: Have had or plan to have surgery on your face, neck, or chin; have had cosmetic treatments on your face, neck, or chin; have had or have medical conditions in or near the neck area; have had or have trouble swallowing; have bleeding problems; are pregnant or plan to become pregnant (it is not known if KYBELLA® will harm your unborn baby); are breastfeeding or plan to breastfeed (it is not known if KYBELLA® passes into your breast milk; talk to your healthcare provider about the best way to feed your baby if you receive KYBELLA®).
Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine).
What are the possible side effects of KYBELLA®?
KYBELLA® can cause serious side effects, including nerve injury in the jaw (which can cause an uneven smile or facial muscle weakness), or trouble swallowing.
The most common side effects of KYBELLA® include: swelling, bruising, pain, numbness, redness, and areas of hardness in the treatment area.
These are not all of the possible side effects of KYBELLA®. Call your healthcare provider for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/safety/MedWatch or call 1-800-FDA-1088.
Please talk to your healthcare provider or visit www.mykybella.com for full Prescribing Information.
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the year ended December 31, 2016. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
1. Allergan, Data on File, Submental Fullness Survey, April 2016.
2. Defatta, Robert, „Liposuction of the Face and Neck”, 2007.
3. Schlessinger, Joel, „Perceptions and Practices in Submental Fat Treatment: A Survey of Physicians and Patients”, SkinMed, Jan/Feb 2013.
4. American Society for Dermatologic Surgery 2015 Consumer Survey on Cosmetic Dermatologic Procedures, 2015. „How Bothered Are You By Excess Fat Under The Chin/Neck?”
5. KYBELLA® Prescribing Information, 2015.
6. Thuangtong R, Bentow J, Knopp K, Mahmood N, David N, Kolodney M. Tissue-Selective Effects of Injected Deoxycholate. American Society for Dermatologic Surgery, Inc. 2010; 36(6):899-908.
7. Data On File, ATX-101-11-22 Clinical Study Report.
8. Data On File, ATX-101-11-23 Clinical Study Report.
SOURCE Allergan plc